Wunderlich Has Buy Rating On ABIOMED (ABMD)

Wunderlich Securities has a Buy rating and a $18 price target on shares of ABIOMED, Inc. ABMD. In a note to clients, Wunderlich writes, "The full Protect II trial data was presented Sunday at the American College of Cardiology (ACC) meeting. As we have suggested, the greater use of atherectomy in the Impella arm of the trial skewed the clinical data and disguised what we believed to be positive data in favor of Impella. With the release of the full data, including the inclusion of an additional 125 patients, we view the Protect II trial as offering the clear clinical evidence of superiority of Impella versus intra-aortic balloon pumps in high-risk PCI patients. We believe this data is strong enough to support Impella's inclusion in the formal ACC/AHA guidelines, which would be a significant catalyst for Impella usage." Shares of ABMD gained 12 cents on Friday to close at $14.65, a gain of 0.8%.